The Estée Lauder Companies has acquired a minority stake in the luxury clinical skincare brand 111SKIN. Founded in 2012 by plastic surgeon Dr. Yannis Alexandrides, 111SKIN specialises in science-led products featuring its proprietary NAC Y2™ technology. The brand offers over 30 products, priced between US$50 and US$1,000, and is available through high-end retailers like Harrods and Nordstrom, as well as luxury spas.
North America represents about 40% of 111SKIN's sales, with additional markets in Europe, the UK, China, and APAC. Direct-to-consumer sales account for roughly 20% of its total revenue. Dr. Alexandrides will continue his involvement with the brand alongside its current management.
This move by Estée Lauder aligns with a clear industry trend: the growing consumer appetite for scientifically validated, performance-driven skincare. As interest in longevity and aesthetic procedures rises, brands offering clinically inspired treatments are gaining traction. Estée Lauder's investment signals its commitment to this segment, but the specific financial terms of the minority stake remain undisclosed.
